SIPULEUCEL-T

Sipuleucel-T Clinical Trials Dendreon currently has ongoing Phase 2 and Phase 3 studies in early and advanced prostate cancer.

Metastatic, castrate resistant (hormone refractory) prostate cancer trials:

• P07-2 (ProACT–treatment of PROstate cancer with Active Cellular ImmunoTherapy), is an ongoing Phase 2 trial currently recruiting participants

Hormone sensitive prostate cancer trials:

• PROTECT (PROVENGE^® (sipuleucel-T) Treatment and Early Cancer Treatment), also known as P-11, is an ongoing Phase 3 trial, but not recruiting participants
• P07-1 (NeoACT–NEOadjuvant Active Cellular ImmunoTherapy) is an ongoing Phase 2 trial currently recruiting participants

This list may not be fully up to date. For current status and more information on our ongoing clinical trials, please visit www.clinicaltrials.gov.